Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ ...
FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) ...
Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ ...
Betsy Salquist Will Provide Specialized Speech and Swallowing Therapy for Patients Living With Parkinson’s Disease.
AstraZeneca’s supplemental Biologics License Application for Imfinzi in combination with enfortumab vedotin has been accepted and granted Priority Review by the US FDA for patients with ...
Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results